During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic ...

Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of ...

Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do ...

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Pembrolizumab alone or in combination with chemotherapy can provide long-term benefits over chemotherapy alone in recurrent or metastatic HNSCC, data suggest.

The drug is now indicated in combination with chemotherapy as a first-line treatment for adult patients with recurrent or metastatic non-keratinizing ... treatment for advanced squamous non-small cell ...

Brain metastasis is emerging as the most serious concern for breast cancer patients. HER2-positive breast cancer is more prone to undergo brain metastasis than other subtypes; notably, there has been ...

Patients with metastatic colorectal cancer who received frontline immune checkpoint inhibitor therapy had positive OS rates ...

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy.

AUGUSTA, Ga. (WJBF)-The average age for someone diagnosed with Kidney Cancer in the U.S. is 65. But one local man’s decades-long battle with cancer began before he was even 10 years old.